Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

766 Features
Roche to announce new breast cancer data

11 Dec 07

Roche to announce new breast cancer data pointing to better survival chances and potential for cure Phase II results suggest Avastin can be used in curative setting
Anne Cameron

Almirall reveals leading edge inhaler for new COPD drug aclidinium bromide

04 Dec 07

Spanish pharmaceutical company Almirall has unveiled a state-of-the-art new dry-powder inhaler in which it plans to market its lead pipeline compound aclidinium bromide for chronic obstructive pulmonary disease (COPD). The device, developed by specialist inhaler company Sofotec, acquired by Almirall in 2006, is set to become the gold standard in inhaler design, claims the company, and will aid patient compliance with anticholinergic medication.
Olwen Glynn Owen - Pharmiweb Field Reporter

PharmiWeb Solutions is expanding

28 Nov 07

Are you keen to join a young, entrepreneurial, fast growth organisation? We'd like to hear from you.
Colin Williams

Pharma ROI – RIP or SOP?

27 Nov 07

PharmiWeb Solutions’ Managing Director Paul Hartigan was a speaker at the annual conference of the Pharmaceutical Marketing Society in London yesterday, November 26th, hosted by the Royal College of Nurses. He reviews his thoughts on the day here.
Editor

Franchising & Novou-Consumerism in Middle East

25 Sep 07

Two things; firstly among all of the great business concepts of the last few decades the franchise model has always surfaced to the very top. Secondly, over the next decade the introduction of hundreds of fresh, locally nurtured franchise concepts emerging within Dubai and the Gulf States will set the stage for a great revolution of nouvo-consumerism. So what are the four key factors driving this movement?
Naseem Javed

PharmiWeb Solutions shortlisted for the Best Online Publisher awards

06 Sep 07

Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP). Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award.
Colin Williams

Novartis, Takeda and B-MS challenging Merck’s market exclusivity in DPP-4 market

07 Aug 07

Merck’s position as the sole provider of an oral antidiabetic drug in the novel dipeptidyl peptidase 4 (DPP 4) inhibitor class is under challenge as at least three companies – Novartis, Takeda and Bristol-Myers Squibb - enter the final stretch of the development process. All four companies presented new data at this year’s American Diabetes Association meeting in Chicago.
Olwen Glynn Owen

BIPOLAR DISORDER: a new holistic approach

30 Jul 07

BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects
Olwen Glynn Owen

Wyeth Reports Earnings Results for the 2007 Second Quarter and First Half

25 Jul 07

Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007 second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to $5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7% for the 2007 second quarter and 8% for the 2007 first half.
Douglas Petkus

Avastin® receives positive opinion in Europe for first-line treatment of patients with advanced lung cancer

20 Jul 07

First medicine shown to extend survival of previously untreated lung cancer patients beyond one year.
Erica Bersin

Market Leading Pharmaceutical Recruitment Consultancy Barrington James Limited is happy to announce the appointment of Tony Kelleher as its Sales Manager

02 Jul 07

Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
Dan Barrington

Erbitux moves to front-line in attack against both metastatic head and neck and colorectal cancers

11 Jun 07

The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
Olwen Glynn Owen

Sponsor a CEO

11 Jun 07

Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra).
Editor

CRYSTAL trial reveals benefits of first-line cetuximab in mCRC

08 Jun 07

Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
Olwen Glynn Owen

Lhasa Acts in Support of Science Education in Africa

05 Jun 07

In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference.
Lhasa Limited

BENEFiT study shows Tracleer (bosentan) improves haemodynamics in CTEPH patients refused surgery

04 Jun 07

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this year’s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition.
Olwen Glynn Owen

So you want to contract staff… what do you need to consider?

23 May 07

In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market.
Paula Mumby

What’s Up (Junior) Doc?

22 May 07

With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe that’s what the MTAS (the Medical Training Application Service - an online application system designed to allow juniors to apply centrally for training rotations) was meant to achieve. However, it had been prone to crashing, and many junior doctors claimed that it was
Paul Hartigan

The Newspaper Cemetery

14 May 07

Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play it’s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket.
Naseem Javed

Beyond biogenerics: the real threats for therapeutic proteins

25 Apr 07

The biogenerics industry consolidates with Indian players emerging in Western countries; pegylation, protein engineering, drug delivery and oral small molecules feed the pipeline of next generation competitors of therapeutic proteins
La Merie Business Intelligence

Europeans in the ‘twilight zone’ of type 2 diabetes care are living under a false sense of security and set to suffer avoidable long-term consequences

23 Apr 07

The results of an in-depth survey of over 750 patients across Europe launched today points to a crisis in the management of the rising numbers of people living in the ‘twilight zone’ of type 2 diabetes care.
Gaja Pellegrini-Bettoli

Wyeth’s Winning Ways: Big Pharma Bounces Back

20 Apr 07

After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry.
Paul Hartigan

eyeforPharma announces dates for New Concept in Interactive Webinar Events to reach more pharma executives online

11 Apr 07

The Sales Technology & CRM Webinar will take place at 15.00 GMT/10.00 EST, 24th May 2007
Richard Bracchi

A Gala Tribute to Global Copycats

03 Apr 07

Over the decade, the art of copying and stealing other people's content and ideas has settled comfortably in the mainstream across the globe. What formerly would constitute an act of piracy is now a commonplace, everyday occurrence. Isn't it time to give these 'borrowers' a tribute, host a gala dinner and hand out awards?
Naseem Javed

Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success

08 Mar 07

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug
La Merie Business Intelligence

TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln

26 Feb 07

Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still no. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4 %), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25 %).
La Merie Business Intelligence

Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26

02 Feb 07

A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26
La Merie Business Intelligence

Global Image Re-Positioning 2007

30 Jan 07

Suddenly, there is a new global tidal wave of change all over the Asian region, the obvious signs are people on the move, new developments and properties popping up all over the region and a nouvo-consumerism is appearing at every corner, customers are buying shiny and wonderful things with beautiful packaging and companies are addressing their hunger with massive blitzes. ...
Naseem Javed

Reducing Risks of Infusion Related Reactions in Targeted Cancer Therapy

30 Jan 07

Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk.
Olwen Glynn Owen

The iPhones, iPains & iProblems

16 Jan 07

The Appendage of the letter "i" to a word as an aim to create an icon is silly…
Naseem Javed

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.